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Dermatology Life Quality Index (DLQI) as a psoriasis referral triage tool 
Dear Editor,  
Most primary care psoriasis referrals in the UK are triaged as ͚routiŶe͛, iŶ part ďeĐause of the 
prioritisation of skin cancer. As a result, patients with severe psoriasis may wait several months to be 
seen, enduring quality of life (QoL) impairment that could have been reduced. Furthermore some 
patients may spontaneously improve by the time they are seen by a specialist, making the 
appointment unnecessary at that time. Therefore, following approval from the local ethics 
committee, we conducted a prospective study to evaluate the usefulness of Dermatology Life 
Quality Index (DLQI) scores in triaging patients with psoriasis referred to our dermatology secondary 
health care services.  
Local general practitioners (GPs) were provided with DLQI questionnaires when referring patients 
with psoriasis. Referrals were triaged as ͚urgeŶt͛ if the DLQI sĐore was > ϭϬ ďeĐause this represeŶts a 
very large effect on a patieŶt͛s life.1 Those referred with no DLQI scores, either from participating or 
non-participating GPs, were triaged as routine, as a control group. When patients were seen in clinic, 
we measured their DLQI and Psoriasis Area and Severity Index (PASI) scores, and satisfaction with 
the waiting time (measured on a five-point Likert scale, 1=Not at all happy to 5=Very happy). A 
power calculation predicted that 20 patients were required in each group to give 80% power to 
detect a five point difference in PASI score for an alpha significance level of 0.05. The 40 recruited 
patients had no significant difference in demographics and disease characteristics (Table 1). The 
ŵediaŶ waitiŶg tiŵe for the ͚urgeŶt͛ group was 88 days (interquartile range (IQR) 66-99 days) 
whereas patieŶts triaged as ͚routiŶe͛ waited Ϯϱϲ days (IQR 228–295 days).  
As expected, of those patients seen urgently 60% were ͚happy͛ or ͚very happy͛ with the waiting time. 
In contrast, in the routine group no patients were ͚happy͛ or ͚very happy͛. The median PASI score in 
the urgent group was 6.2 (IQR 3.5–10.6) compared to 3.85 (IQR 2.8–6.3) in the routine group (no 
significant difference). The median DLQI score in the urgent group when seen in secondary care was 
four points higher compared to the routine group (urgent=16, IQR 12-20, vs. routine=12, IQR 8.5–
17). In those triaged as urgent, the median DLQI score was not significantly different compared to 
their baseline scores at the time of referral (17.5; IQR 13.5–23).  
Pressures on dermatology secondary care services in the UK and a requirement to meet skin cancer 
waiting time targets results in patients with inflammatory dermatoses having long waiting times.  
Triaging GP referrals accurately is difficult if information is incomplete and disease severity scores 
are not given. Asking GPs to perform a severity score involving complete skin examination, such as 
PASI, is not practical because of lack of time and insufficient training. However, a QoL questionnaire 
can easily be completed by patients while the GP documents the consultation. The DLQI is the most 
commonly used QoL assessment tool in psoriasis trials2 and takes 1-2 minutes to complete.3 Patients 
seen urgently due to a baseline DLQI score > 10 at referral had a DLQI score four points higher than 
those referred without a DLQI and seen ͚routinely͛. As the minimal clinically important difference 
(MCID) for DLQI is four points,4 using a baseline DLQI score greater than 10 does identify those 
patients whose psoriasis has a particularly high impact on QoL, compared to an unselected group of 
psoriasis referrals. 
One limitation is the lack of a separate group of psoriasis referrals with a DLQI score ≤10. However 
we found that almost no patients were referred with scores in this range, perhaps because GPs 
chose not to refer less severely affected patients. The Scottish5 and Malaysian6 guidelines 
recommend referral for DLQI scores >5 in psoriasis patients unresponsive to topical therapy and, in 
keeping with our study experience, 65.5% of eligible patients in Scotland were not seen by a 
specialist.7 It is possible that patients or GPs might inflate DLQI scores to reduce waiting time delays, 
however we mitigated this in our study by not specifying the DLQI score triage cut-off for urgent 
appointments.  
Our long waiting time of 256 days for routine referrals reflects pressures on dermatology secondary 
care services in Wales. While we chose a DLQI cut off score of 10 points, as it indicates major 
impairment of QoL, a different cut off score could be selected depending on the attitude and 
resources of the referral centre.  
In summary, we have demonstrated that a QoL instrument such as the DLQI can be used as a triage 
tool. Its use may help GPs quantify psoriasis severity, and ensure that patients whose psoriasis is 
causing greatest impact on QoL are seen in a timely manner. A much larger randomised study is 
needed to evaluate the usefulness of DLQI as a triage tool in dermatology services. 
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Table 1 Participants’ characteristics. HT: hypertension; IQR: interquartile range; PsA: Psoriatic arthritis.  
 Routine (no DLQI at referral) Urgent (DLQI > 10 at referral) 
Number  20 20 
Gender  M=9; F=11 M=11; F=9 
Age median (years) (IQR) 34 (28-51) 40 (33–52) 
Psoriasis duration median (years) (IQR) 13 (8.5-20) 8.5 (4-20) 
Body Mass Index (BMI) (median kg/m2) (IQR) 27.1 (23.4–31.2) 29.2 (26–33.5) 
Family history of psoriasis  10 9 
Co-morbidities 11 (HT=5; 
hypercholesterolaemia=2; 
depression=8) 
8 (HT=4; DM=1; 
hypercholesterolaemia=2; 
depression=2; PsA=2) 
Waiting time median (days) (IQR) 256 days (228–295) 88 days (66–99) 
 
